Ascendis Pharma A/S $ASND Holdings Boosted by Diversified Trust Co

Diversified Trust Co lifted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 17.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 30,581 shares of the biotechnology company’s stock after purchasing an additional 4,590 shares during the quarter. Diversified Trust Co’s holdings in Ascendis Pharma A/S were worth $6,967,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Perceptive Advisors LLC lifted its stake in Ascendis Pharma A/S by 41.6% in the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock worth $350,282,000 after purchasing an additional 450,000 shares in the last quarter. Sei Investments Co. grew its position in shares of Ascendis Pharma A/S by 24.8% during the 1st quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company’s stock valued at $80,318,000 after purchasing an additional 69,673 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Ascendis Pharma A/S by 27.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 227,013 shares of the biotechnology company’s stock valued at $51,602,000 after purchasing an additional 48,275 shares in the last quarter. Frazier Life Sciences Management L.P. grew its position in shares of Ascendis Pharma A/S by 68.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock valued at $60,053,000 after purchasing an additional 91,822 shares in the last quarter. Finally, Orbimed Advisors LLC increased its holdings in shares of Ascendis Pharma A/S by 5.8% in the first quarter. Orbimed Advisors LLC now owns 181,977 shares of the biotechnology company’s stock worth $41,624,000 after purchasing an additional 10,000 shares during the period.

Ascendis Pharma A/S Stock Up 3.1%

Shares of NASDAQ:ASND opened at $275.39 on Friday. The stock has a market capitalization of $17.18 billion, a P/E ratio of 18.00 and a beta of 0.40. The stock’s 50-day moving average price is $242.67 and its 200-day moving average price is $239.83. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. Ascendis Pharma A/S has a 12-month low of $188.08 and a 12-month high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The firm had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 44.80% and a net margin of 73.26%. On average, equities analysts anticipate that Ascendis Pharma A/S will post 3.43 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ASND shares. Cantor Fitzgerald lifted their price objective on Ascendis Pharma A/S from $300.00 to $315.00 and gave the company an “overweight” rating in a research note on Friday. Morgan Stanley decreased their target price on Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 1st. Raymond James Financial restated an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Friday. Barclays lowered their price target on Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Finally, HC Wainwright dropped their price target on Ascendis Pharma A/S from $344.00 to $335.00 and set a “buy” rating for the company in a research report on Friday. Nineteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $313.52.

Key Headlines Impacting Ascendis Pharma A/S

Here are a few of the latest headlines about ASND:

• Positive Sentiment: Q3 results and commercial growth were strong. Ascendis reported revenue of $418.7 million, above analyst expectations, while product revenue reached €366 million, up 89% year over year. YORVIPATH accounted for €291 million of product sales. The company also reported a quarterly profit, marking a shift toward commercial-scale profitability. Ascendis Pharma Q3 2026 results
• Positive Sentiment: Analyst updates lean bullish. TD Cowen raised its target to $352 and UBS lifted its target to $315, both maintaining buy ratings. Cantor Fitzgerald also raised its target to $315 with an overweight rating; RBC reaffirmed outperform at $290. These higher targets indicate continued analyst confidence in the outlook. Read More. · Read More. · Read More. · Read More.
• Negative Sentiment: Employee warrants may cause modest dilution. Ascendis granted 28,030 employee warrants, creating a potential increase in shares outstanding if exercised. Read More.

Insider Activity

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total transaction of $810,570.00. Following the transaction, the senior vice president directly owned 3,000 shares of the company’s stock, valued at approximately $810,570. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.